History of Myasthenia Gravis Revisited

Feza Deymeer1

  • 1İstanbul University Faculty of Medicine Retired Faculty Member, İstanbul, Turkey.

Insights

This review traces the 150-year history of myasthenia gravis (MG) research, highlighting key discoveries in its pathophysiology and treatment. It details advancements from early clinical descriptions to modern immunotherapies and surgical interventions for MG.

Area of Science:

  • Neurology
  • Immunology
  • Medical History

Background:

  • Myasthenia gravis (MG) has a documented history dating back to 1672.
  • Significant advancements in understanding and treating MG have occurred over the last 150 years.
  • This review systematically examines the historical progression of MG research and clinical practice.

Purpose of the Study:

  • To provide a systematic review of the historical evolution of myasthenia gravis research.
  • To chronicle the key scientific and clinical milestones in understanding MG.
  • To present the experience of Istanbul University in managing myasthenia gravis.

Main Methods:

  • Historical analysis of myasthenia gravis literature and clinical practice.
  • Categorization of MG history into four distinct periods (1868-1930, 1930-1960, 1960-1990, 1990-2020).
  • Review of diagnostic and therapeutic advancements throughout these periods.

Main Results:

  • The first period (1868-1930) defined MG's clinical features and initiated studies on neuromuscular transmission.
  • The second period (1930-1960) identified acetylcholine as the neurotransmitter and introduced anticholinesterases and thymectomy.
  • The third period (1960-1990) revolutionized MG treatment with immunosuppressants and mechanical ventilation, clarifying its autoimmune basis.
  • The fourth period (1990-2020) saw discoveries like anti-MuSK antibodies, minimally invasive surgery, and new therapeutic agents.

Conclusions:

  • Myasthenia gravis research has progressed significantly, transforming from basic clinical observation to complex immunological understanding and targeted therapies.
  • The development of diagnostic tools, understanding of autoimmune mechanisms, and introduction of novel treatments have dramatically improved MG patient outcomes.
  • Istanbul University has played a pioneering role in advancing MG care in Turkey.

Related Concept Videos

Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
2.2K
Myasthenia Gravis: Diagnostic Tests01:15

Myasthenia Gravis: Diagnostic Tests

Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
1.6K
Disorders of the Skeletal Muscle01:28

Disorders of the Skeletal Muscle

The clinical conditions affecting the skeletal muscle tissue are broadly categorized as musculoskeletal and neuromuscular disorders.
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...
1.3K
Chemical Synapses01:26

Chemical Synapses

Chemical synapses are specialized sites between two neurons or between a neuron and a non-neuronal cell like a muscle, glandular or sensory cell.
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...
10.3K
Chemical Synapses01:26

Chemical Synapses

Chemical synapses are specialized sites between two neurons or between a neuron and a non-neuronal cell like a muscle, glandular or sensory cell.
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...
3.6K
Muscle Contraction01:10

Muscle Contraction

In skeletal muscles, acetylcholine is released by nerve terminals at the motor endplate—the point of synaptic communication between motor neurons and muscle fibers. The binding of acetylcholine to its receptors on the sarcolemma allows entry of sodium ions into the cell and triggers an action potential in the muscle cell. Thus, electrical signals from the brain are transmitted to the muscle. Subsequently, the enzyme acetylcholinesterase breaks down acetylcholine to prevent excessive...
7.9K